Meng Wei, Chen Bo, Jiang Zhaosheng, Cai Bo, Ma Limin, Guan Yangbo
Department of Urology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
Transl Cancer Res. 2023 Aug 31;12(8):2071-2098. doi: 10.21037/tcr-23-227. Epub 2023 Aug 23.
Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cell carcinoma. The myosin 6 (MYO6) plays an important role in tumorigenesis and progression. However, its prognostic and immunological effects in ccRCC have not been comprehensively and systematically studied. Therefore, this study aimed to investigate the prognostic value and immune-related role of MYO6 in ccRCC.
The expression of MYO6 mRNA and protein in normal and tumor tissues using The Cancer Genome Atlas (TCGA) and other public databases were analyzed. In order to further improve the accuracy of the results, immunohistochemistry (IHC) was performed to verify the results. R software, an integrated repository portal for tumor-immune system interactions (TISIDB) and other online analysis tools were used to investigate the relationship between MYO6 expression and clinicopathological features, diagnostic and prognostic value, and the level of immune infiltration in patients with ccRCC. MYO6 genomic alterations were then investigated using the cBio Cancer Genomics Portal (cBioPortal) database. Gene Ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis and Gene Set Enrichment Analysis (GSEA) enrichment analysis were used to elucidate the biological processes and signaling pathways. Finally, a protein interaction network was constructed using Biological Universal Repository for Interactive Datasets (BioGRID) and some online analysis tools to investigate the correlation between MYO6 and its co-expressed genes in ccRCC patients.
In the present study, MYO6 expression was significantly reduced in ccRCC tumors compared with normal tissues.This was consistent with the results of immunohistochemistry. Lower MYO6 expression levels were significantly associated with higher cancer grade and later TNM stage in ccRCC. Compared with the MYO6 high expression group, ccRCC patients with low MYO6 expression had a poor prognosis of overall survival (OS). MYO6 expression has diagnostic and prognostic potential in ccRCC. MYO6 expression is associated with different tumor-infiltrating immune cells, especially macrophages.
The findings suggest that reduced MYO6 expression levels are associated with disease progression, poor prognosis, and immune cell infiltration, and can be considered as a promising prognostic biomarker for ccRCC.
透明细胞肾细胞癌（ccRCC）是肾细胞癌最常见的类型。肌球蛋白6（MYO6）在肿瘤发生和进展中起重要作用。然而，其在ccRCC中的预后和免疫作用尚未得到全面系统的研究。因此，本研究旨在探讨MYO6在ccRCC中的预后价值及免疫相关作用。
利用癌症基因组图谱（TCGA）和其他公共数据库分析正常组织和肿瘤组织中MYO6 mRNA和蛋白的表达。为进一步提高结果的准确性，进行免疫组织化学（IHC）验证结果。使用R软件、肿瘤-免疫系统相互作用综合存储库门户（TISIDB）和其他在线分析工具，研究MYO6表达与ccRCC患者临床病理特征、诊断和预后价值以及免疫浸润水平之间的关系。然后使用cBio癌症基因组学门户（cBioPortal）数据库研究MYO6基因组改变。采用基因本体（GO）/京都基因与基因组百科全书（KEGG）富集分析和基因集富集分析（GSEA）富集分析来阐明生物学过程和信号通路。最后，使用交互式数据集生物通用存储库（BioGRID）和一些在线分析工具构建蛋白质相互作用网络，以研究ccRCC患者中MYO6与其共表达基因之间的相关性。
在本研究中，与正常组织相比，ccRCC肿瘤中MYO6表达显著降低。这与免疫组织化学结果一致。较低的MYO6表达水平与ccRCC中较高的癌症分级和较晚的TNM分期显著相关。与MYO6高表达组相比，MYO6低表达的ccRCC患者总生存期（OS）预后较差。MYO6表达在ccRCC中具有诊断和预后潜力。MYO6表达与不同的肿瘤浸润免疫细胞相关，尤其是巨噬细胞。
研究结果表明，MYO6表达水平降低与疾病进展、预后不良和免疫细胞浸润相关，可被视为ccRCC有前景的预后生物标志物。
